Lateral lymph node dissection reduces local recurrence of locally advanced lower rectal cancer in the absence of preoperative neoadjuvant chemoradiotherapy: a systematic review and meta-analysis

Gao, Xiang; Wang, Cun; Yu, Yongyang; Singh, Dujanand; Yang, Lie; Zhou, Zongguang

doi:10.1186/s12957-020-02078-1

Table 2 Characteristics of the 12 included studies

From: Lateral lymph node dissection reduces local recurrence of locally advanced lower rectal cancer in the absence of preoperative neoadjuvant chemoradiotherapy: a systematic review and meta-analysis

Study	Study year(region)	Research type	Group name	Sample size	Mean age(years)	Sex ratio(M:F)	Median follow-up time	Tumor location	Clinical stage	Preoperative therapy regimen (n)	Postoperative therapy regimen (n)	Indication of LLND	Type of LLND	Type of TME	Matching criteria
Nagawa, H	2001(Japan)	RCTs	TME+LLND	23	59.1(± 10.1)^b	17:6	N/A	Middle, low	Stage B, C ^Ω	50Gy (2 Gy/day5 days/week5 weeks) (23)	5-FU-based chemotherapy (23)	Random controlledallocation	Bilateral LLND	LAR, APR	A, B, C, D, E, F, H, I
Nagawa, H	2001(Japan)	RCTs	TME alone	22	60.1(± 8.8)^b	16:6	N/A	Middle, low	Stage B, C ^Ω	50 Gy (2 Gy/day5 days/week5 weeks) (22)	5-FU-based chemotherapy (22)	Random controlledallocation	No	LAR, APR	A, B, C, D, E, F, H, I
Fujita, S	2003(Japan)	Retrospective	TME+LLND	204	57(± 10)^b	133:71	59 months	Middle, low	TNM II/III	No	No	No lateral lymph nodes metastases	Bilateral LLND	LAR, APR	A, B, C, D, E, F, G, H, I
Fujita, S	2003(Japan)	Retrospective	TME alone	42	64(± 12)^b	24:18	59 months	Middle, low	TNM II/III	No	No	No lateral lymph nodes metastases	No	LAR, APR	A, B, C, D, E, F, G, H, I
Kusters, M	2009(Japan and Netherlands)	Retrospective	TME + LLND	324	58(± 11)^b	215:109	7.9 years	Middle, low	TNM II/III	No	Postoperative chemoradiotherapy (27)	Non-restriction but the same inclusion criteria in the two arms	Unilateral and bilateral LLND	LAR, APR	B, C, D, E, F, G, I
Kusters, M	2009(Japan and Netherlands)	Retrospective	TME alone	376	64(± 11)^b	234:142	7.0 years	Middle, low	TNM II/III	No	Postoperative chemoradiotherapy (61)		No	LAR, APR	B, C, D, E, F, G, I
Watanabe, T	2002(Japan)	Retrospective	TME + LLND	75	N/A	N/A	N/A	Middle, low	Stage B, C ^Ω	50 Gy(2 Gy/day5 days/week5 weeks) (75)	No	No lateral lymph nodes metastases	Bilateral LLND	LAR, APR, or Hartmann	A, B, C, D, E, G, H, I
Watanabe, T	2002(Japan)	Retrospective	TME alone	40	N/A	N/A	N/A	Middle, low	Stage B, C ^Ω	50 Gy(2 Gy/day5 days/week5 weeks) (40)	No	No lateral lymph nodes metastases	NO	LAR, APR, or Hartmann	A, B, C, D, E, G, H, I
Fujita, S	2012(Japan)	RCTs	TME + LLND	351	61(54–67)^a	236:115	N/A	Middle, low	TNM II/III	No	5-FU-based chemotherapy (163)	Random controlledallocation	Bilateral LLND	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Fujita, S	2012(Japan)	RCTs	TME alone	350	62(55–68)^a	236:114	N/A	Middle, low	TNM II/III	No	5-FU-based chemotherapy (153)	Random controlledallocation	NO	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Dev, K	2017(India)	RCT	TME + LLND	163	N/A	N/A	N/A	Middle, low	TNM II/III	25 Gy(5 Gy*5) (163)	NO	Random controlledallocation	Bilateral LLND	TME without explaining the details	A, B, C, D, E, F, G, H, I
Dev, K	2017(India)	RCT	TME alone	77	N/A	N/A	N/A	Middle, low	TNM II/III	25 Gy(5 Gy*5) (77)	NO	Random controlledallocation	NO	TME without explaining the details	A, B, C, D, E, F, G, H, I
Saito, S	2016(Japan)	RCTs	TME + LLND	351	61(55–66)^a	N/A	N/A	Middle, low	TNM II/III	No	5-FU-based chemotherapy (163)	Random controlledallocation	Bilateral LLND	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Saito, S	2016(Japan)	RCTs	TME alone	350	62(56–69)^a	N/A	N/A	Middle, low	TNM II/III	No	5-FU-based chemotherapy (153)	Random controlledallocation	NO	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Fujita, S	2017(Japan)	RCTs	TME + LLND	351	61(26–75)^@	236:115	72.2 months	Middle, low	TNM II/III	No	5-FU-based chemotherapy (163)	Random controlledallocation	Bilateral LLND	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Fujita, S	2017(Japan)	RCTs	TME alone	350	62(26–75)^@	236:114	72.2 months	Middle, low	TNM II/III	No	5-FU-based chemotherapy (153)	Random controlledallocation	NO	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Ito, Masaaki	2018(Japan)	RCTs	TME + LLND	351	61(26–75)^@	236:115	N/A	Middle, low	TNM II/III	No	5-FU-based chemotherapy (163)	Random controlledallocation	Bilateral LLND	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Ito, Masaaki	2018(Japan)	RCTs	TME alone	350	62(26–75)^@	236:114	N/A	Middle, low	TNM II/III	No	5-FU-based chemotherapy (153)	Random controlledallocation	NO	LAR, APR, or Hartmann	A, B, C, D, E, F, G, H, I
Oki, Eiji	2019(Japan)	Prospective	TME + LLND	215	60.7(± 9.4)^b	159:56	5 years	Middle, low	TNM II/III	No	5-FU-based chemotherapy (215)	Random controlledallocation	Bilateral LLND	LAR, APR, Hartmann, or Others	B, C, D, E, F, G, H, I
Oki, Eiji	2019(Japan)	Prospective	TME alone	230	63.5(± 8.9)^b	151:79	5 years	Middle, low	TNM II/III	No	5-FU-based chemotherapy (230)	Random controlledallocation	NO	LAR, APR, Hartmann, or Others	B, C, D, E, F, G, H, I
Ozawa, H	2016(Japan)	Retrospective	TME+LLND	499	N/A	356:143	N/A	Middle, low	TNM II/III	No	Postoperative chemotherapy (193)	Non-restriction but the same inclusion criteria in the two arms	Bilateral LLND	LAR, APR, or Others	A, B, C, D, E, F, I
Ozawa, H	2016(Japan)	Retrospective	TME alone	499	N/A	334:165	N/A	Middle, low	TNM II/III	No	Postoperative chemotherapy (207)		NO	LAR, APR, or Others	A, B, C, D, E, F, I
Ogura	2019(Japan)	Retrospective	TME+LLND	98	N/A	N/A	56.5 (55.0–58.1) ^@	Middle, low	TNM II/III	45-50.4 Gy/25 Gy + oxaliplatin-based/5-FU-based chemotherapy (98)	Partial patients received adjuvant chemotherapy	Non-restriction but the same inclusion criteria in the two arms	Bilateral LLND	LAR, APR, Hartmann, ISR, or TPE	C, D, E, F,
Ogura	2019(Japan)	Retrospective	TME alone	870	N/A	N/A	56.5 (55.0–58.1) ^@	Middle, low	TNM II/III	45-50.4 Gy/25 Gy + oxaliplatin-based/5-FU-based chemotherapy (870)	Partial patients received adjuvant chemotherapy		NO	LAR, APR, Hartmann, ISR, or TPE	C, D, E, F,

For matching criteria A = year, B = sex, C = tumor location, D = neo-adjuvant, E = adjuvant, F = lateral lymph-node status, G = lymph and vessel invasive H = tumor differentiation I = lateral lymph node status, Ω Astler-Coller staging system, @ values are presented as the median (range), FU fluorouracil, Gy LAR low anterior resection, APRA abdominoperineal resection, Hartmann Hartmann’s procedure
^aValues are presented as the median (IQR)
^bValues are presented as the mean ± standard deviation

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us